Rejuvenation Technologies Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- Investors
-
16
Rejuvenation Technologies General Information
Description
Developer of a telomere extender designed for regenerative medicine. The company's extender encodes telomerase reverse transcriptase, which is delivered to cells to transiently increase telomerase activity for extending telomeres, which increases the proliferative capacity of the cells, enabling patients to target age-related diseases and conditions, including in the hepatic, pulmonary, and immunology spaces.
Contact Information
Website
www.rejuvenationtech.comCorporate Office
- 415 Clyde Avenue
- Unit 107
- Mountain View, CA 94043
- United States
Corporate Office
- 415 Clyde Avenue
- Unit 107
- Mountain View, CA 94043
- United States
Rejuvenation Technologies Timeline
Rejuvenation Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 16-Sep-2026 | Completed | Pre-Clinical Trials | |||
| 6. Seed Round | 26-Feb-2025 | Completed | Pre-Clinical Trials | |||
| 5. Accelerator/Incubator | 10-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 05-Sep-2023 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 25-Sep-2022 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series 3) | 31-Dec-2021 | $1M | Completed | Pre-Clinical Trials | ||
| 1. Accelerator/Incubator | 01-Aug-2018 | $1M | $1M | Completed | Startup |
Rejuvenation Technologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Plus 1 | ||||||||
| Seed Plus 6 | ||||||||
| Seed Plus 5 | ||||||||
| Seed Plus 4 | ||||||||
| Seed Plus 3 | 758,483 | $0.000010 | $1.89 | $1.89 | 1x | $1.89 | 4.21% | |
| Seed Plus 2 | 5,205,685 | $0.000010 | $0.79 | $0.79 | 1x | $0.79 | 28.92% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Rejuvenation Technologies Comparisons
Industry
Financing
Details
Rejuvenation Technologies Competitors (57)
One of Rejuvenation Technologies’s 57 competitors is Akero Therapeutics, a Corporate Backed or Acquired company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Akero Therapeutics | Corporate Backed or Acquired | South San Francisco, CA | ||||
| ImmunoMet | Venture Capital-Backed | Houston, TX | ||||
| Thetis Pharmaceuticals | Venture Capital-Backed | Essex, CT | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY |
Rejuvenation Technologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rejuvenation Technologies Patents
Rejuvenation Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236316-A1 | Methods and compositions for the treatment of short telomere-related hematologic disorders | Pending | 07-May-2025 | ||
| WO-2025049632-A1 | Compositions and methods for broad delivery of rna to tissue | Inactive | 29-Aug-2023 | ||
| WO-2025049632-A9 | Compositions and methods for broad delivery of rna to tissue | Inactive | 29-Aug-2023 | ||
| AU-2023334154-A1 | Compositions and methods for delivery of rna | Pending | 30-Aug-2022 | ||
| EP-4580609-A2 | Compositions and methods for delivery of rna | Pending | 30-Aug-2022 | A61K47/6929 |
Rejuvenation Technologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rejuvenation Technologies Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jetstream Venture Fund | Venture Capital | Minority | ||
| Makai VC | Venture Capital | Minority | ||
| Endless Frontier Labs | Accelerator/Incubator | Minority | ||
| Deep Ventures (Venture Capital) | Venture Capital | Minority | ||
| Global Black Syndicate | Venture Capital | Minority |
Rejuvenation Technologies FAQs
-
When was Rejuvenation Technologies founded?
Rejuvenation Technologies was founded in 2016.
-
Where is Rejuvenation Technologies headquartered?
Rejuvenation Technologies is headquartered in Mountain View, CA.
-
What is the size of Rejuvenation Technologies?
Rejuvenation Technologies has 20 total employees.
-
What industry is Rejuvenation Technologies in?
Rejuvenation Technologies’s primary industry is Drug Discovery.
-
Is Rejuvenation Technologies a private or public company?
Rejuvenation Technologies is a Private company.
-
What is Rejuvenation Technologies’s current revenue?
The current revenue for Rejuvenation Technologies is .
-
How much funding has Rejuvenation Technologies raised over time?
Rejuvenation Technologies has raised $14.6M.
-
Who are Rejuvenation Technologies’s investors?
Jetstream Venture Fund, Makai VC, Endless Frontier Labs, Deep Ventures (Venture Capital), and Global Black Syndicate are 5 of 16 investors who have invested in Rejuvenation Technologies.
-
Who are Rejuvenation Technologies’s competitors?
Akero Therapeutics, ImmunoMet, Thetis Pharmaceuticals, AnTolRx, and Cognition Therapeutics are some of the 57 competitors of Rejuvenation Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
